Who is sponsoring NCT05284448?

NCT05284448 is sponsored by Al-Azhar University.

What drugs are being tested in NCT05284448?

Interventions in NCT05284448: pentoxifylline (Trental SR®).

What condition does NCT05284448 study?

NCT05284448 studies NASH - Nonalcoholic Steatohepatitis.

Is NCT05284448 still recruiting?

NCT05284448 is currently completed. Last updated 21 June 2024.

Last reviewed 2024-06-21 · How we verify

NCT05284448

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis

Completed Phase 3 Last updated 21 June 2024

What this trial tests

Phase 3 trial testing pentoxifylline (Trental SR®) in NASH - Nonalcoholic Steatohepatitis in 50 participants. Completed in 1 October 2022.

Timeline

1 February 2022

Primary endpoint
1 September 2022

1 October 2022

Quick facts

Lead sponsor	Al-Azhar University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 February 2022
Primary completion	1 September 2022
Estimated completion	1 October 2022
Sites	1 location across Egypt

Drugs / interventions tested

pentoxifylline (Trental SR®) — full drug profile →

Conditions studied

NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →

Sponsor

Al-Azhar University

Who can join

Adults 18 to 65, any sex, with NASH - Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study is to evaluate the efficacy and safety of pentoxifylline in the treatment of non-alcoholic steatohepatitis patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S, Kim J, Lee JY, Kim J, et al · · 2023 · cited 45× · PMID 38049180 · DOI 10.7570/jomes23054
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y, Wang W, Morgan MP, Robson T, et al · · 2023 · cited 37× · PMID 37361533 · DOI 10.3389/fendo.2023.1148934
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
Hu Y, Sun C, Chen Y, Liu YD, et al · · 2024 · cited 31× · PMID 39280073 · DOI 10.14218/jcth.2024.00123
Oligonucleotide therapies for nonalcoholic steatohepatitis.
Li S, Xiong F, Zhang S, Liu J, et al · · 2024 · cited 19× · PMID 38665220 · DOI 10.1016/j.omtn.2024.102184
Cyclic nucleotide phosphodiesterases as drug targets.
Kelly MP, Nikolaev VO, Gobejishvili L, Lugnier C, et al · · 2025 · cited 14× · PMID 40081105 · DOI 10.1016/j.pharmr.2025.100042
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.
Alonso-Peña M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, et al · · 2023 · cited 11× · PMID 37445895 · DOI 10.3390/ijms241310718
Targeting Metabolism: Innovative Therapies for MASLD Unveiled.
Wang W, Gao X, Niu W, Yin J, et al · · 2025 · cited 3× · PMID 40362316 · DOI 10.3390/ijms26094077
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options.
Ren R, Liang X, Wei X. · · 2026 · PMID 42215843 · DOI 10.1186/s43556-026-00486-5

Verify or expand the search:

Other recruiting trials for NASH - Nonalcoholic Steatohepatitis

Currently open trials in the same condition.

NCT05499949 — The Franciscus Obesity NASH Study · active not recruiting
NCT05023044 — Nonalcoholic Fatty Liver Disease in HIV Database · active not recruiting
NCT04232566 — Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity · recruiting
NCT05165446 — Novel MRE Technique to Assess a Risk Factor for Liver Cancer · active not recruiting
NCT04697810 — Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) · Phase 2 · recruiting

Other Al-Azhar University trials

Trials by the same sponsor.

NCT06489327 — Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery · NA · recruiting
NCT07327918 — Effect of Epidural Needle Injection on Catheter Placement Success During Painless Labour · Phase 3 · not yet recruiting
NCT07500194 — Quad Helix vs RME for Posterior Cross-bite in Egyptian Children · NA · not yet recruiting
NCT07360756 — Ultrasonographic ONSD as a Predictor of PDPH in Spinal Anesthesia for Cesarean Delivery · not yet recruiting
NCT07343570 — Comparison of Quadratus Lumborum and Combined Groin Nerve Blocks for Postoperative Analgesia After Open Inguinal Hernia · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05284448 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Al-Azhar University
Last refreshed: 21 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05284448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing